AAPL   318.32 (-0.18%)
MSFT   182.47 (-0.57%)
FB   233.18 (-0.74%)
GOOGL   1,428.06 (+1.05%)
AMZN   2,426.24 (-0.44%)
NVDA   349.90 (-3.09%)
BABA   202.90 (+1.60%)
GE   6.87 (+7.18%)
TSLA   820.35 (+0.42%)
AMD   53.87 (-2.36%)
T   31.10 (+4.08%)
F   5.88 (+3.89%)
GILD   73.55 (+0.29%)
NFLX   414.69 (-3.41%)
BAC   24.57 (+8.43%)
BA   145.73 (+5.96%)
AAPL   318.32 (-0.18%)
MSFT   182.47 (-0.57%)
FB   233.18 (-0.74%)
GOOGL   1,428.06 (+1.05%)
AMZN   2,426.24 (-0.44%)
NVDA   349.90 (-3.09%)
BABA   202.90 (+1.60%)
GE   6.87 (+7.18%)
TSLA   820.35 (+0.42%)
AMD   53.87 (-2.36%)
T   31.10 (+4.08%)
F   5.88 (+3.89%)
GILD   73.55 (+0.29%)
NFLX   414.69 (-3.41%)
BAC   24.57 (+8.43%)
BA   145.73 (+5.96%)
AAPL   318.32 (-0.18%)
MSFT   182.47 (-0.57%)
FB   233.18 (-0.74%)
GOOGL   1,428.06 (+1.05%)
AMZN   2,426.24 (-0.44%)
NVDA   349.90 (-3.09%)
BABA   202.90 (+1.60%)
GE   6.87 (+7.18%)
TSLA   820.35 (+0.42%)
AMD   53.87 (-2.36%)
T   31.10 (+4.08%)
F   5.88 (+3.89%)
GILD   73.55 (+0.29%)
NFLX   414.69 (-3.41%)
BAC   24.57 (+8.43%)
BA   145.73 (+5.96%)
AAPL   318.32 (-0.18%)
MSFT   182.47 (-0.57%)
FB   233.18 (-0.74%)
GOOGL   1,428.06 (+1.05%)
AMZN   2,426.24 (-0.44%)
NVDA   349.90 (-3.09%)
BABA   202.90 (+1.60%)
GE   6.87 (+7.18%)
TSLA   820.35 (+0.42%)
AMD   53.87 (-2.36%)
T   31.10 (+4.08%)
F   5.88 (+3.89%)
GILD   73.55 (+0.29%)
NFLX   414.69 (-3.41%)
BAC   24.57 (+8.43%)
BA   145.73 (+5.96%)
Log in

NASDAQ:KZIAKazia Therapeutics Stock Price, Forecast & News

$2.77
-0.04 (-1.42 %)
(As of 05/26/2020 03:32 PM ET)
Add
Compare
Today's Range
$2.77
Now: $2.77
$2.77
50-Day Range
$2.59
MA: $2.80
$3.08
52-Week Range
$2.24
Now: $2.77
$9.74
Volume200 shs
Average Volume32,437 shs
Market Capitalization$20.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZIA
CUSIPN/A
CIKN/A
Phone61-2-9472-4101

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book Value$1.63 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$20.00 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

How has Kazia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KZIA stock has decreased by 30.4% and is now trading at $2.77. View which stocks have been most impacted by Coronavirus.

Has Kazia Therapeutics been receiving favorable news coverage?

Headlines about KZIA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kazia Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutKazia Therapeutics.

Who are some of Kazia Therapeutics' key competitors?

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), General Motors (GM), Pembina Pipeline (PBA), Abeona Therapeutics (ABEO), Acer Therapeutics (ACER), Achillion Pharmaceuticals (ACHN), Acasti Pharma (ACST), Adamis Pharmaceuticals (ADMP) and Advaxis (ADXS).

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill, Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications
  • Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Morgan Stanley (1.10%) and UBS Group AG (0.12%).

Which institutional investors are buying Kazia Therapeutics stock?

KZIA stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, and Morgan Stanley.

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $2.77.

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $20.00 million and generates $1.12 million in revenue each year. The company earns $-7,340,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.